TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 4,200 shares of its common stock and restricted stock units covering 7,250 shares of its common stock to 10 newly-hired employees, with a grant date of January 18, 2023 (the “Grant Date”). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.